1Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer[ J]. J Clin Oncol, 1992,10 : 1775 - 1780. 被引量：1
2Jagasia MH, Langer CJ, Johnson DH, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase Ⅱ study [ J ]. Clin Cancer Res, 2001,7 ( 1 ) : 68 -73. 被引量：1
3Cardenal F, Domine M, Massuti B, et al. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase Ⅱstudy[ J ]. Lung Cancer,2003,39 (2) :201 - 207. 被引量：1
4Saito H,Kudoh S, Nakagawa K,et al. Phase Ⅱ study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-eell lung cancer E J 1. Am J Clin Oneol, 2006,29 ( 5 ) : 503 - 507, 被引量：1
5Hino M, Kobayashi K, Yoshimura A, et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer [ J ]. Anticancer Res,2006 ,26 (6C) :4697 - 4703. 被引量：1
6Negoro S, Masuda N, Takada Y, et al. Randomised phase Ⅲtrial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer[ J]. Br J Cancer,2003,88:335 -341. 被引量：1
7Ohe Y,Ohashi Y,Kubota K,et al. Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan [J]. Ann Oncol,2007,18(2) :317 -323. 被引量：1
8Ziotopoulos P, Androulakis N, Mylonaki E, et al. Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel : a multicentre phase Ⅱ study [ J ]. Lung Cancer, 2005,50( 1 ) :115 - 122. 被引量：1
9Han JY, Lee DH, Lee SY, et al. Phase Ⅱ study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma [ J ]. Cancer, 2005, 104 (12) :2759 -2765. 被引量：1
10Okamoto I, Nishimura T, Miyazaki M, et al. Phase Ⅱ study of combination therapy with S-1 and irinotecan for advanced nonsmall cell lung cancer: west Japan thoracic oncology group 3505 [ J ]. Clin Cancer Res, 2008,14 (16) :5250 - 5254. 被引量：1
4Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer,1981,47(1): 207-214. 被引量：1
5Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in ad vanced non small cell lung cancer: a meta-analysis. Lancet, 1993,342(8862) : 19-21. 被引量：1
6Non small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BM J, 1995,311(7010): 899-909. 被引量：1
7Ceresoli GL, Gregorc V, Cordio S, et al. Phase Ⅱ study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. Lung Cancer,2004,44(2): 231-239. 被引量：1
8Serke M, Schoenfeld N, Loddenkemper R. Weekly docetaxel as second line chemotherapy in advanced non-small cell lung cancer:phase Ⅱ trial. AnticancerRes,2004,24(2C): 1211-1216. 被引量：1
9Park YH, Lee JC, Kim CH, et al. Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum. Jpn J Clin Oncol, 2004,34 (5): 245-249. 被引量：1
10Georgoulias V, Kouroussis C, Agelidou A, et al. Irinotecan plus gemcitabine vs irinotecan for the second line treatment of patients with advanced non-small cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase Ⅱ study. Br J Cancer,2004,91(3): 482-488. 被引量：1
